Tvardi Therapeutics Inc Sustainability Reports
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3. Its lead programs focus on treating fibrosis-driven diseases, inflammatory disorders, and proliferative conditions such as hepatocellular carcinoma.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300COVOY41P0GZ881
FIGI: BBG001V0GHL4
1 reports from 2025 to 2025
